PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
PF-06741086 Long-term Treatment in Severe Hemophilia
- Conditions
- Hemophilia A or B
- Interventions
- Biological: PF-06741086
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT03363321
- Locations
- π¨π±
Hospital Dr. Sotero del Rio, Santiago, Puente ALTO, Chile
π§π·Centro de Hematologia e Hemoterapia de Campinas- Hemocentro de Campinas, Campinas, SAO Paulo, Brazil
π¨πUniversitatsSpital Zurich, Zurich, Switzerland
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Genetic: PF-06939926
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT03362502
- Locations
- πΊπΈ
Primary Children's Hospital, Salt Lake City, Utah, United States
πΊπΈUniversity of Utah Clinical Neurosciences Center, Salt Lake City, Utah, United States
πΊπΈRonald Reagan UCLA Medical Center - Interventional Radiology, Los Angeles, California, United States
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 137
- Registration Number
- NCT03356977
- Locations
- πΊπΈ
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
πΊπΈBaumann Cosmetic and Research Institute, Miami, Florida, United States
πΊπΈTexas Dermatology and Laser Specialists, San Antonio, Texas, United States
Bioequivalence (BE) Study Comparing Azithromycin 250 mg Tablet Manufactured in China and in the United States
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT03353480
- Locations
- π¨π³
The First Hospital of Jilin University/Phase I Clinical Trials Unit, Changchun, Jilin, China
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PF-06372865Drug: Placebo
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT03351751
- Locations
- πΊπΈ
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 387
- Registration Number
- NCT03349060
- Locations
- π¨π¦
Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada
πΊπΈCalifornia Dermatology & Clinical Research Institute, Encinitas, California, United States
πΊπΈForward Clinical Trials, Inc., Tampa, Florida, United States
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT03343054
- Locations
- π―π΅
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
π―π΅Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan
π―π΅National Hospital Organization Osaka National Hospital, Osaka, Japan
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
- Conditions
- Systemic Lupus ErythematosusRheumatoid Arthritis
- Interventions
- Drug: PF-06835375Drug: Placebo
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 74
- Registration Number
- NCT03334851
- Locations
- πΊπΈ
Wallace Rheumatic Studies Center, Beverly Hills, California, United States
πΊπΈPrive aftercare, Los Angeles, California, United States
πΊπΈPinnacle Research Group, LLC, Anniston, Alabama, United States
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
- Conditions
- Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 223
- Registration Number
- NCT03330405
- Locations
- πΊπΈ
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
πΊπΈNYU Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
πΊπΈFreidenrich Center for Translational Research (CTRU), Palo Alto, California, United States
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) Β± Metronidazole (MTZ) Versus Meropenem (MER) Β± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
- Conditions
- Complicated Intra-abdominal InfectionHosptial Acquired PneumoniaVentilator Associated Pneumonia
- Interventions
- Drug: ATM-AVIDrug: MERDrug: MTZDrug: COL
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 422
- Registration Number
- NCT03329092
- Locations
- π¬π·
General Hospital of Athens "Laiko", Athens, Greece
π¬π·Koutlimbaneio and Triantafylleio General Hospital of Larissa, Larissa, Greece
ππ·Clinical Hospital Dubrava, Zagreb, Croatia